Advertisement

Central European Journal of Medicine

, Volume 2, Issue 4, pp 488–498 | Cite as

Biweekly CHOP therapy improves therapeutic effect in the non-GCB subtype of diffuse large B-cell lymphoma

  • Qingyuan Zhang
  • Jingxuan Wang
  • Jincai Wang
Research Article
  • 49 Downloads

Abstract

CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) is accepted as the best available standard treatment for diffuse large B-cell lymphoma (DLBCL) patients; however, the therapeutic efficacy seems unsatisfactory. Additional rituximab will improve the cure rate, but it is not popular in China because of its increased medical cost. Germinal center B-cell (GCB) and non-GCB subtypes distinction have been described as independent prognostic factors, and provides likelihood for cure with chemotherapy. The aim of the study is to explore the association between Immunophenotype and treatment regimen. Between August 2003 and May 2006, 66 patients with DLBCL were enrolled, according to immunohistochemistry results (GCB and non-GCB phenotype), randomly assigned to receive either six to eight cycles of CHOP every 2 weeks or standard CHOP every 3 weeks. After a median follow-up duration of 32 months (range of 4 to 42 months), an estimated 3-year overall survival (OS) rate for the GCB patients were 68.2% and 55.6% for the biweekly CHOP regimen and standard CHOP regimen respectively, while the data were 62.8% and 37.9% respectively for the non-GCB cases. The biweekly CHOP therapy showed higher efficacy than standard treatment, and its superiority was more obvious with the non-GCB subgroup. All rights reserved.

Keywords

Diffuse large B-cell lymphoma (DLBCL) GCB non-GCB CHOP 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    B. Coiffier, E. Lepage and J. Briere: “CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma”, N. Engl. Med., Vol. 346, (2002), pp. 235–242.CrossRefGoogle Scholar
  2. [2]
    P. Feugier, A. Van Hoof and C. Sebban: “Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Grouped Etude des Lymphomes del Adulte”, J. Clin. Oncol., Vol. 23, (2005), pp. 4117–4126.PubMedCrossRefGoogle Scholar
  3. [3]
    T.M. Habermann, E.A. Weller and V.A. Morrison: “Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma”, J. Clin. Oncol., Vol. 24, (2006), pp. 3121–3127.PubMedCrossRefGoogle Scholar
  4. [4]
    C.P. Hans, D.D. Weisenburger and T.C. Greiner: “Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray”, Blood, Vol. 103, (2004), pp. 275–282.PubMedCrossRefGoogle Scholar
  5. [5]
    A.A. Alizadeh, M.B. Eisen and R.E. Davis: “Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling”, Nature, Vol. 403, (2000), pp. 503–511.PubMedCrossRefGoogle Scholar
  6. [6]
    A.I. Saez, A.J. Saez and M.J. Artiga: “Building an outcome predictor model for diffuse large B-cell lymphoma”, Am. J. Pathol., Vol. 164, (2004), pp. 613–622.PubMedGoogle Scholar
  7. [7]
    A. Dogan, E. Bagdi and P. Munson: “CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas”, Am. J. Surg. Pathol., Vol. 24, (2000), pp. 846–852.PubMedCrossRefGoogle Scholar
  8. [8]
    B. Faleni and D.Y. Mason: “Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry”, Blood, Vol. 99, (2002), pp. 409–426.CrossRefGoogle Scholar
  9. [9]
    B. Falini, M. Fizzotti and A. Pucciarini: “A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells”, Blood, Vol. 95, (2000), pp. 2084–2092.PubMedGoogle Scholar
  10. [10]
    M.M. Oken, R.H. Creech and D.C. Tormey: “Toxicity and response criteria of the Eastern Cooperative Oncology Group”, Am. J. Clin. Oncol., Vol. 5, (1982), pp. 569–573.CrossRefGoogle Scholar
  11. [11]
    P.P. Carbone, H.S. Kaplan and K. Musshoff: “Report of the committee on Hodgkin’s disease staging classification”, Cancer Res., Vol. 31, (1971), pp. 1860–1861.PubMedGoogle Scholar
  12. [12]
    The international non-Hodgkin’s lymphoma prognostic factors project: “A predictive model for aggressive non-Hodgkin’s lymphoma”, N. Engl. J. Med., Vol. 329, (1993), pp. 987–994.CrossRefGoogle Scholar
  13. [13]
    B.D. Cheson, S.J. Homing and B. Coiffier: “Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphoma”, J. Clin. Oncol., Vol. 17, (1999), pp. 1244–1253.PubMedGoogle Scholar
  14. [14]
    B.H. Ye, P.H. Rao and R.S. Chaganti: “Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma”, Cancer Res., Vol. 53, (1993), pp. 2732–2735.PubMedGoogle Scholar
  15. [15]
    B. Coiffier: “Increasing chemotherapy intensity in aggressive lymphomas: a renewal?”, J. Clin. Oncol., Vol. 13, (2003), pp. 2457–2459.CrossRefGoogle Scholar
  16. [16]
    V.A. Morrison, V. Picozzi and S. Scott: “The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’ lymphoma receiving initial CHOP chemotherapy: a risk factor analysis”, Clinical Lymphoma, Vol. 2, (2001), pp. 47–56.PubMedCrossRefGoogle Scholar
  17. [17]
    T. Philip, C. Guglielmi and R. Somers: “Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma”, N. Eng. J. Med., Vol. 333, (1995), pp. 1540–1545.CrossRefGoogle Scholar
  18. [18]
    A.M. Gianni, M. Bredni and S. Siena: “High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma”, N. Engl. J. Med., Vol. 336, (1997), pp. 1290–1297.PubMedCrossRefGoogle Scholar
  19. [19]
    M.A. Shipp, M.D. Abeloff and K.H. Antman: “International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury”, J. Clin. Oncol., Vol. 17, (1999), pp. 423–429.PubMedGoogle Scholar
  20. [20]
    K. Itoh, T. Ohtsu and H. Fukuda: “Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated GCSF) in aggressive non-Hodgkin’s lymphoma: Japan Clinical Oncology Group Study 9505”, Ann. Oncol., Vol 13, (2002), pp. 1347–1355.PubMedCrossRefGoogle Scholar
  21. [21]
    D.C. Betticher, G. Martinelli and J.A. Radford: “Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)”, Annals of Oncology, Vol. 17, (2006), pp. 1546–1552.PubMedCrossRefGoogle Scholar
  22. [22]
    D.W. Blayney, B.W. McGuire and S.E. Cruickshank: “Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin’s lymphoma”, Oncologist, Vol. 10, (2005), pp. 138–149.PubMedCrossRefGoogle Scholar
  23. [23]
    M. Pfreundschuh, L. Trümper and M. Kloess: “Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL”, Blood, Vol. 104, (2004), pp. 626–633.PubMedCrossRefGoogle Scholar
  24. [24]
    M. Pfreundschuh, L. Trümper and M. Kloess: “Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the SHNHL”, Blood, Vol. 104, (2004), pp. 634–641.PubMedCrossRefGoogle Scholar
  25. [25]
    M. Daliu, Z. Xiaoyan and L. Hongfeng: “BCL 6, CD10 and BCL 2 protein expression in B cell non-Hodgkin’s lymphoma and its clinicopathologic significance”, China oncology, Vol. 16, (2006), pp. 169–173.Google Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  1. 1.Department of Medical OncologyTumor Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations